|
[1]YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.
|
|
[2]KIM GA,LEE HC,CHOE J,et al.Association between nonalcoholic fatty liver disease and cancer incidence rate[J].J Hepatol,2017.[Online ahead of print]
|
|
[3]STARLEY BQ,CALCAGNO CJ,HARRISON SA.Nonalcoholic fatty liver disease and hepatocellular carcinoma:A weighty connection[J].Hepatology,2010,51(5):1820-1832.
|
|
[4]VERNON G,BARANOVA A,YOUNOSSI ZM.Systematic review:The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274-285.
|
|
[5]BEDOGNI G,BELLENTANI S,MIGLIOLI L,et al.The Fatty LiverIndex:A simple and accurate predictor of hepatic steatosis in the general population[J].BMC Gastroenterol,2006,6:33.
|
|
[6]KOTRONEN A,PELTONEN M,HAKKARAINEN A,et al.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors[J].Gastroenterology,2009,137(3):865-872.
|
|
[7]KOOT BG,van der BAAN-SLOOTWEG OH,BOHTE AE,et al.Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children[J].Obesity(Silver Spring),2013,21(3):583-590.
|
|
[8]WANG J,XU C,XUN Y,et al.ZJU index:A novel model for predicting nonalcoholic fatty liver disease in a Chinese population[J].Sci Rep,2015,5:16494.
|
|
[9]LI L,YOU W,REN W.The ZJU index is a powerful index for identifying NAFLD in the general Chinese population[J].Acta Diabetol,2017,54(10):905-911.
|
|
[10]POYNARD T,RATZIU V,NAVEAU S,et al.The diagnostic value of biomarkers(SteatoTest)for the prediction of liver steatosis[J].Comp Hepatol,2005,4:10.
|
|
[11]HE L,DENG L,ZHANG Q,et al.Diagnostic value of CK-18,FGF-21,and related biomarker panel in nonalcoholic fatty liver disease:A systematic review and Meta-analysis[J].Biomed Res Int,2017,2017:9729107.
|
|
[12]ANTY R,IANNELLI A,PATOURAUX S,et al.A new composite model including metabolic syndrome,alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients[J].Aliment Pharmacol Ther,2010,32(11-12):1315-1322.
|
|
[13]GRIGORESCU M,CRISAN D,RADU C,et al.A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis[J].J Physiol Pharmacol,2012,63(4):347-353.
|
|
[14]ALKHOURI N,ALISI A,OKWU V,et al.Circulating soluble fasand fas ligand levels are elevated in children with nonalcoholic steatohepatitis[J].Dig Dis Sci,2015,60(8):2353-2359.
|
|
[15]QI S,XU D,LI Q,et al.Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis[J].Clin Chim Acta,2017,473:89-95.
|
|
[16]UCHIHARA M,IZUMI N.High-sensitivity C-reactive protein(hs-CRP):A promising biomarker for the screening of nonalcoholic steatohepatitis(NASH)[J].Nihon Rinsho,2006,64(6):1133-1138.
|
|
[17]BOGA S,KOKSAL AR,ALKIM H,et al.Plasma pentraxin 3 differentiates nonalcoholic steatohepatitis(NASH)from non-NASH[J].Metab Syndr Relat Disord,2015,13(9):393-399.
|
|
[18]ZHANG X,SHEN J,MAN K,et al.CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis[J].J Hepatol,2014,61(6):1365-1375.
|
|
[19]SHEN J,CHAN HL,WONG GL,et al.Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers[J].J Hepatol,2012,56(6):1363-1370.
|
|
[20]TIETGE UJ,SCHMIDT HH,SCHUTZ T,et al.Reduced plasma adiponectin in NASH:Central obesity as an underestimated causative risk factor[J].Hepatology,2005,41(2):401;author reply 401-402.
|
|
[21] YONEDA M,NOZAKI Y,ENDO H,et al.Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis(NASH)independent of HFE gene mutation[J].Dig Dis Sci,2010,55(3):808-814.
|
|
[22]KOWDLEY KV,BELT P,WILSON LA,et al.Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J].Hepatology,2012,55(1):77-85.
|
|
[23]OKANOUE T,EBISE H,KAI T,et al.A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis[J].J Gastroenterol,2018,53(1):129-139.
|
|
[24]LIU CH,AMPUERO J,GIL-GOMEZ A,et al.miRNAs in patients with non-alcoholic fatty liver disease:A systematic review and meta-analysis[J].J Hepatol,2018,69(6):1335-1348.
|
|
[25]PIROLA CJ,FERNANDEZ GIANOTTI T,CASTANO GO,et al.Circulating microRNA signature in non-alcoholic fatty liver disease:From serum non-coding RNAs to liver histology and disease pathogenesis[J].Gut,2015,64(5):800-812.
|
|
[26]BECKER PP,RAU M,SCHMITT J,et al.Performance of serum microRNAs-122,-192 and-21 as biomarkers in patients with non-alcoholic steatohepatitis[J].PLoS One,2015,10(11):e0142661.
|
|
[27]YOUNOSSI ZM,LOOMBA R,ANSTEE QM,et al.Diagnostic modalities for non-alcoholic fatty liver disease(NAFLD),non-alcoholic steatohepatitis(NASH)and associated fibrosis[J].Hepatology,2017,68(1):349-360.
|
|
[28]POYNARD T,RATZIU V,CHARLOTTE F,et al.Diagnostic value of biochemical markers(NashTest)for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease[J].BMC Gastroenterol,2006,6:34.
|
|
[29]ZHOU Y,ORESIC M,LEIVONEN M,et al.Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites[J].Clin Gastroenterol Hepatol,2016,14(10):1463-1472.e6.
|
|
[30]HANSEN JF,JUUL NIELSEN M,NYSTROM K,et al.PROC3:A new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C[J].Scand J Gastroenterol,2018,53(1):83-87.
|
|
[31] DANIELS SJ,LEEMING DJ,ESLAM M,et al.ADAPT:An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis[J].Hepatology,2019,69(3):1075-1086.
|
|
[32]CHERNBUMROONG S,GROVE JI,ASTBURY S,et al.Advanced machine learning techniques to identify a panel of biomarkers that identify nonalcoholic steatohepatitis[J].Hepatol-ogy,2017,66(S1):53A-54A.
|
|
[33]POLYZOS SA,SLAVAKIS A,KOUMERKERIDIS G,et al.Noninvasive liver fibrosis tests in patients with nonalcoholic fatty liver disease:An external validation cohort[J].Horm Metab Res,2019,51(2):134-140.
|
|
[34]TANWAR S,TREMBLING PM,GUHA IN,et al.Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease[J].Hepatology,2013,57(1):103-111.
|
|
[35]SUZUKI A,ANGULO P,LYMP J,et al.Hyaluronic acid,an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease[J].Liver Int,2005,25(4):779-786.
|
|
[36]ABDELAZIZ R,ELBASEL M,ESMAT S,et al.Tissue inhibitors of metalloproteinase-1 and 2 and obesity related non-alcoholic fatty liver disease:Is there a relationship[J].Digestion,2015,92(3):130-137.
|
|
[37]LICHTINGHAGEN R,PIETSCH D,BANTEL H,et al.The Enhanced Liver Fibrosis(ELF)score:Normal values,influence factors and proposed cut-off values[J].J Hepatol,2013,59(2):236-242.
|
|
[38]XIAO G,ZHU S,XIAO X,et al.Comparison of laboratory tests,ultrasound,or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease:A meta-analysis[J].Hepatology,2017,66(5):1486-1501.
|
|
[39]European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH clinical practice guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol,2015,63(1):237-264.
|
|
[40]ADAMS LA,GEORGEJ,BUGIANESI E,et al.Complex noninvasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol,2011,26(10):1536-1543.
|
|
[41]RATZIU V,MASSARD J,CHARLOTTE F,et al.Diagnostic value of biochemical markers(FibroTest-FibroSURE)for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease[J].BMC Gastroenterol,2006,6:6.
|
|
[42]ZHANG YL,MA YJ,WANG ZL,et al.Evaluation of four scoring systems in diagnosis of hepatic fibrosis in patients with nonalcoholic fatty liver disease[J].Chin J Modern Med,2017,27(22):112-126.(in Chinese)张意兰,马英杰,王志凌,等.4种评分系统在非酒精性脂肪肝病肝纤维化程度的诊断效能评价[J].中国现代医学杂志,2017,27(22):112-126.
|
|
[43]GUO ZQ,WANG QY,QI XS,et al.Recommendations for the diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases(2017)[J].J Clin Hepatol,2017,33(12):2275-2277.(in Chinese)郭泽淇,王倩怡,祁兴顺,等.《2017年美国肝病学会非酒精性脂肪性肝病诊疗指导》摘译[J].临床肝胆病杂志,2017,33(12):2275-2277.
|
|
[44]National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association.Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J].J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
|
DownLoad: